353 related articles for article (PubMed ID: 29901296)
1. [The effects of combination therapy with 5-reductase inhibitor and -blocker on the prognosis of BPH].
Neimark AI; Davydov AV; Aliev RT
Urologiia; 2018 May; (2):62-66. PubMed ID: 29901296
[TBL] [Abstract][Full Text] [Related]
2. [Combination drug therapy in patients with BPH].
Kuzmenko AV; Kuzmenko VV; Gyaurgiev TA
Urologiia; 2018 Mar; (1):101-105. PubMed ID: 29634142
[TBL] [Abstract][Full Text] [Related]
3. [Approaches to medical management of patients with high risk of progressing of benign prostatic hyperplasia depending on concomitant erectile dysfunction].
Kamalov AA; Takhirzade AM
Urologiia; 2018 Jul; (3):70-77. PubMed ID: 30035422
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Characteristics of Benign Prostatic Hyperplasia (BPH) Patients Treated with Finasteride and Alpha Blocker Combination Therapy Versus Alpha Blocker Monotherapy in China: An Analysis of Electronic Medical Record Data.
Fu Y; Han S; Wang L; Gao W; Wu E; Cao X; Wang J
Adv Ther; 2018 Aug; 35(8):1191-1198. PubMed ID: 30014350
[TBL] [Abstract][Full Text] [Related]
5. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
Morlock R; Goodwin B; Gomez Rey G; Eaddy M
Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
[TBL] [Abstract][Full Text] [Related]
6. Combination of α-blocker and 5α-reductase inhibitor for treatment of benign prostatic hyperplasia.
Kang D; Hu C; Fu Y; Wang D
Clin Invest Med; 2017 Oct; 40(5):E200-E210. PubMed ID: 29061225
[TBL] [Abstract][Full Text] [Related]
7. Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study.
Lin VC; Liao CH; Kuo HC
Urology; 2014 Feb; 83(2):416-21. PubMed ID: 24332123
[TBL] [Abstract][Full Text] [Related]
8. Management of benign prostate hyperplasia (BPH) by combinatorial approach using alpha-1-adrenergic antagonists and 5-alpha-reductase inhibitors.
Zitoun OA; Farhat AM; Mohamed MA; Hamad MR; Aramini B; Haider KH
Eur J Pharmacol; 2020 Sep; 883():173301. PubMed ID: 32592768
[TBL] [Abstract][Full Text] [Related]
9. Comparison of α-blocker monotherapy and α-blocker plus 5α-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia.
Joo KJ; Sung WS; Park SH; Yang WJ; Kim TH
J Int Med Res; 2012; 40(3):899-908. PubMed ID: 22906262
[TBL] [Abstract][Full Text] [Related]
10. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial.
Bjerklund Johansen TE; Baker TM; Black LK
BJU Int; 2012 Mar; 109(5):731-8. PubMed ID: 21933326
[TBL] [Abstract][Full Text] [Related]
12. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
13. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
Silva J; Silva CM; Cruz F
Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacoeconomic evaluation of combination therapy with dutasteride and α1 blocker for treatment of benign prostatic hyperplasia in Japan].
Takayama T; Arakawa I; Kakihara H; Tachibana K; Ozono S
Hinyokika Kiyo; 2012 Feb; 58(2):61-9. PubMed ID: 22450830
[TBL] [Abstract][Full Text] [Related]
15. Long-term risk of benign prostatic hyperplasia-related surgery and acute urinary retention in men treated with 5-alpha reductase inhibitor versus alpha-blocker monotherapy in routine clinical care.
Bengtsen MB; Heide-Jørgensen U; Borre M; Nørgaard M
Prostate; 2023 Jul; 83(10):980-989. PubMed ID: 37057816
[TBL] [Abstract][Full Text] [Related]
16. Transitional Zone Index as a Predictor of the Efficacy of α-Blocker and 5α-Reductase Inhibitor Combination Therapy in Korean Patients with Benign Prostatic Hyperplasia.
Choi JD; Kim JH; Ahn SH
Urol Int; 2016; 96(4):406-12. PubMed ID: 26824527
[TBL] [Abstract][Full Text] [Related]
17. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
[TBL] [Abstract][Full Text] [Related]
18. Real-world use of Permixon® in benign prostatic hyperplasia--determining appropriate monotherapy and combination treatment.
Perry R; Milligan G; Anderson P; Gillon A; White M
Adv Ther; 2012 Jun; 29(6):538-50. PubMed ID: 22644964
[TBL] [Abstract][Full Text] [Related]
19. [Tadalafil in patients with benign prostatic hyperplasia during conservative combined therapy].
Volkov AA; Petrichko MI; Budnik NV; Dukhin AR
Urologiia; 2013; (2):56, 58-9. PubMed ID: 23789365
[TBL] [Abstract][Full Text] [Related]
20. [Benign prostate hyperplasia: success and limitations of pharmacological therapy].
Madersbacher S; Marszalek M
Internist (Berl); 2007 Oct; 48(10):1157-64. PubMed ID: 17426942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
